Settlement Overview

DISCLAIMER: Maryland’s Office of Overdose Response is developing an interactive dashboard to share information about prescription opioid settlement funds in Maryland. The content here will be removed once the dashboard is live. This information may also be updated on a regular basis. 

As of the 2025 fiscal year (July 1, 2024 – June 30, 2025), Maryland has received distributions through eight prescription opioid-related legal settlements. Maryland’s Opioid Restitution Fund was established in 2019 to receive any funds distributed at the state level, whether designated for use at the state’s discretion or to be distributed to local subdivisions. 

Maryland’s Settlement Framework

The State-Subdivision Agreements of 2022 and 2023 specify how funds will be shared between the state and all participating subdivisions. In Maryland, 70% of funds subject to this agreement are distributed at the local level. In addition to State Finance and Procurement Article § 7–331, which outlines allowable uses for these funds as outlined in Exhibit E, the State-Subdivision Agreements also identifies additional parameters for allowable spending in Maryland. 

Funding Breakdown

There are four distinct funding streams for settlements in the National Opioid Settlement.

Local Subdivisions (70%)

Local subdivisions receive 70% of the total funds through two funding streams: 

• Local Direct (25%): Local Direct allocation payments go directly from the settlement administrator, Brown Greer, PLC, to participating subdivisions. 

• Targeted Abatement Grants (TAG) (45%): TAG funds are deposited into the state ORF account, but are strictly to be used to provide formula-based grants to the participating subdivisions. Upon submission and approval of a Local Abatement Plan (LAP) demonstrating a plan for allowable spending that is compliant with the State-Subdivision Agreement, opioid settlement agreements, and applicable law, those funds may be released by MOOR to the local subdivision. Targeted Abatement Grant funds cannot be utilized by the state.

There are eight qualifying charter counties that are not required to submit a LAP due to an agreement made during the settlement process: Anne Arundel County, Baltimore City (only for the Walmart settlement), Baltimore County, Frederick County, Harford County, Howard County, Montgomery County, and Prince George’s County.

State Portion (30%)

Funds at the state level are split between the State Allocation and State Discretionary Abatement Fund.

• State Allocation (15%): Used for allowable expenditures at the state’s discretion. Legislative mandates should come from this fund. 

• State Discretionary Abatement Fund (SDAF) (15%): The SDAF is required to be made available through competitive grants.

Finalized Settlements (as of Fiscal Year 2025)

IMPORTANT NOTE: The details below may differ from the most recent Opioid Restitution Fund Annual Expenditure Report. The information on this page is periodically updated with more recent information.

As of August 2025, Maryland has received payments from eight different settlements, including: 

• Mallinckrodt
• McKinsey & Company
• Janssen (includes McKesson, Cencora, and Cardinal Health)
• Walmart
• Walgreens
• Allergan
• Teva
• Publicis Health

NOTE: Our coming ORF Dashboard will include a projection table with more detailed information about these settlement projections. 

Five of the eight settlements are part of the National Opioid Settlement; Mallinckrodt, McKinsey, and Publicis are not and have different allocation formulas and guiding principles. In 2024, Maryland reached a settlement agreement with Kroger, payments through which will begin in fiscal year 2026. 

In 2025, Maryland reached settlement agreements with Purdue Pharma and the following distributors: Alvogen, Amneal, Apotex, Hikma, Mylan (now part of Viatris), Sun, and Zydus. Settlement award amounts and a payment schedule for these settlements are not available at this time. Under settlements with current payment schedules, Maryland will receive payments until fiscal year 2038. Some settlements use front-loaded payments, and the amount received will decrease each year.

Apart from national settlements, McKinsey, Mallinckrodt, and Publicis payments that go to the state will fall in the State Allocation fund. Mallinkrodt (also known as “NOAT-II”) also has local payment distributions to counties, which can be found here. Publicis does not have local subdivision payments. 

Funds Received

As of the end of the 2025 fiscal year, the State of Maryland has received $192,260,874.59. These funds were distributed as follows: 

• $97,015,609.83 was designated as TAG funds, 
• $37,960,873.19 was designated as State Discretionary Abatement Fund grants
• $57,284,391.70 was designated for the State Allocation
• $53,580,085.23 was sent directly from the settlement administrator to local subdivisions. 

Together, the total amount of ORF funding paid to Maryland was $245,840,960.82. You can view the current projected payment schedule for the national settlement here. 

For the non-national opioid settlements, McKinsey has paid its full settlement amount of $12,084,129.00 as of fiscal year 2025, and Publicis paid out its one-time payment of $7,239,389.04 in the 2024 fiscal year. Mallinckrodt has paid out the total settlement amount of $2,200,943.11. Mallinckrodt also has local payment distributions to counties, which can be found here. 

Summary

Based on current projections, a total of $670,823,954.48 will be received by Maryland and its subdivisions over the next 18 years. Of this, $160,093,417 will be distributed directly to local subdivisions, $284,763,252.13 will be distributed to local subdivisions through TAG distributions, $122,014,862.59 will be designated for the State Allocation, and $100,490,400.97 will be designated for State Discretionary Abatement Fund grants. 

As of FY25, $90,909,835.84 of prescription opioid settlement funds have been expended or allocated for use in future years. To learn more about how Maryland is using these funds, visit our Use of ORF Funds page.